Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10162653 | 0.93 | PTGDR2 (0.45) | PTGDR2EPAS1PTGDREGFRERBB2 | |
| SCHEMBL586217 | 0.92 | PTGDR2 (0.44) | PTGDR2EPAS1PTGDREGFRERBB2 | |
| SCHEMBL585800 | 0.90 | EPAS1 (0.46) | PTGDR2EPAS1PTGDREGFRERBB2 | |
| SCHEMBL585990 | 0.88 | PTGDR2 (0.44) | PTGDR2EPAS1RORC | |
| SCHEMBL10162778 | 0.87 | PTGDR2 (0.41) | PTGDR2EPAS1PTGDREGFRERBB2 | |
| SCHEMBL585797 | 0.85 | PTGDR2 (0.45) | PTGDR2EPAS1PTGDREGFRERBB2 | |
| SCHEMBL585493 | 0.83 | EPAS1 (0.42) | PTGDR2EPAS1EGFRERBB2RORC | |
| SCHEMBL586570 | 0.82 | PTGDR2 (0.54) | PTGDR2EPAS1PTGDR | |
| SCHEMBL14490991 | 0.81 | EPAS1 (0.47) | PTGDR2EPAS1PTGDR | |
| SCHEMBL585257 | 0.81 | PTGDR2 (0.46) | PTGDR2EPAS1RORCSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963259-B1 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| EP-2305640-A2 | Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | PNMT, SQOR, SMS | PTGDR2 120/4885EPAS1 299/4885PTGDR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.